Across TCGA pan-cancer cohorts, ARHGEF28 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated ARHGEF28 data layer compared with 5 for mutation status and 7 for mass-spec protein.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher ARHGEF28 RNA is associated with better overall survival. In most high-consensus cancer types, elevated ARHGEF28 expression acts as an unfavorable survival marker, although some lineages such as KIRC and READ show a favorable association.
KIRC, UVM, and KIRP are the cancer types where ARHGEF28 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.